A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035)

Part of paid clinical trials in Tempe, Arizona.

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT06880874
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • Enlicitide — DRUG
    Oral Tablet

Study Details

The goal of the study is to learn what happens to different forms of enlicitide medications in a healthy person's body over time. Researchers will compare the amount of enlicitide in the healthy person's body over time when enlicitide is given in different formulations.

Key Dates

Start date
Apr 2, 2025
Status verified
Jun 2025
Primary completion
May 16, 2025
Completion
May 31, 2025

Study Design

Enrollment
40 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Treatment A: enlicitide reference tablet
    Participants receive a single oral dose of enlicitide reference tablet.
  • Experimental: Treatment B: enlicitide test tablet
    Participants receive a single oral dose of enlicitide test tablet.

Primary Outcome Measure

Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC0-24hrs) of enlicitide in plasma [ Time Frame: Pre-dose and at designated time points up to 24 hours post dose ]

Locations (1)

FacilityCityStateZIPSite coordinators
Celerion ( Site 0001)TempeArizona85283-

Find similar trials in Tempe, AZ

By research site
Celerion· Tempe, AZ

Related Studies